Category Archives: September 2014

Does ‘evidence’ from big data, using data from electronic health records, really mean what it appears to mean?

The precision of genome sequencing (e.g. the 1000 genome project) is extraordinary, and it is now also remarkably ‘cheap’.  Randomised clinical trials of pharmaceuticals are rigorous.  However, what use is genomic data without phenotypic data to understand its meaning? How … Continue reading

Posted in September 2014 | Tagged , | Leave a comment